This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A phase 2, randomized, open label study to evaluat...
Clinical trial

A phase 2, randomized, open label study to evaluate the efficacy, safety, pharmacodynamics, pharmacokinetics of the anti-ALK-1 MAB PF-03446962 in combination with best supportive care vs. best supportive care alone in adult patients with advanced hepatoce

Read time: 1 mins
Last updated:11th Apr 2014

To determine whether overall survival (OS) of PF-03446962 plus best supportive care (BSC) is superior to OS of BSC in patients with advanced HCC following sorafenib failure.

Category Value
Study start date 2014-04-11

View full details